Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VSIR | Q9H7M9 | 1/20 | 0.37 |
| ▸ | TARS1 | P26639 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 2/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.36 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.35 |
| ▸ | SHMT1 | P34896 | 2/20 | 0.35 |
| ▸ | SHMT2 | P34897 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3563528 | 0.88 | MCL1 (0.42) | VSIRAURKAAURKBLIPGSERPINE1 | |
| SCHEMBL5010329 | 0.88 | SMN1; SMN2 (0.40) | VSIRTARS1AURKAAURKBLIPG | |
| SCHEMBL3558995 | 0.86 | ALDH1A1 (0.41) | SHMT1SHMT2SMN1; SMN2PPARD | |
| SCHEMBL3559572 | 0.85 | HSD17B1 (0.43) | TP53MAPTSMN1; SMN2 | |
| SCHEMBL3092625 | 0.84 | NPC1 (0.43) | VSIRAURKAAURKBLIPGSERPINE1 | |
| SCHEMBL3560339 | 0.82 | MCL1 (0.46) | SERPINE1SHMT1SHMT2TP53SMN1; SMN2 | |
| SCHEMBL14259221 | 0.81 | SMN1; SMN2 (0.39) | VSIRTARS1LIPGSERPINE1TP53 | |
| SCHEMBL3105076 | 0.80 | XDH (0.39) | MAPT | |
| SCHEMBL3558074 | 0.80 | HSD17B3 (0.41) | SMN1; SMN2 | |
| SCHEMBL5011218 | 0.80 | MCL1 (0.41) | SERPINE1SHMT1SHMT2TP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7659412-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER HEALTHCARE LLC (US) | 2010-02-09 | — | — | US | disclosed |
| US-20090023783-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | ZHANG CHENGZHI | 2009-01-22 | — | — | US | disclosed |
| US-7420066-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
| US-20060194816-A1 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAER PHAMACEUTICALS CORPORATION (US) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194816-A1 | Benzofuran derivatives useful for treating hyper-proliferative disorders | MKI67, PCNA, CCNI | VSIR 4822/4885TARS1 2669/4885AURKA 3520/4885 |
| US-20090023783-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | PCNA, MKI67, CDK4 | VSIR 4696/4885TARS1 2977/4885AURKA 3326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.